Johnson & Johnson $JNJ Shares Sold by Meritage Portfolio Management

Meritage Portfolio Management trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 5.2% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 76,756 shares of the company’s stock after selling 4,169 shares during the period. Johnson & Johnson comprises 0.9% of Meritage Portfolio Management’s investment portfolio, making the stock its 19th biggest holding. Meritage Portfolio Management’s holdings in Johnson & Johnson were worth $14,232,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently made changes to their positions in JNJ. Evolution Wealth Management Inc. purchased a new position in shares of Johnson & Johnson during the second quarter worth $27,000. Clayton Financial Group LLC acquired a new position in Johnson & Johnson during the 3rd quarter worth about $28,000. Semmax Financial Advisors Inc. boosted its holdings in Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after acquiring an additional 72 shares during the period. GFG Capital LLC acquired a new position in Johnson & Johnson in the 2nd quarter valued at about $35,000. Finally, Signature Resources Capital Management LLC increased its stake in Johnson & Johnson by 262.9% during the third quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock worth $47,000 after purchasing an additional 184 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 0.3%

Johnson & Johnson stock opened at $218.81 on Friday. The stock has a market cap of $527.18 billion, a PE ratio of 21.12, a P/E/G ratio of 2.25 and a beta of 0.34. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The stock’s fifty day moving average is $205.82 and its two-hundred day moving average is $186.95. Johnson & Johnson has a 1-year low of $141.50 and a 1-year high of $220.11.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is 50.19%.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on JNJ shares. Loop Capital set a $190.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 22nd. Daiwa America upgraded shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Barclays increased their price objective on Johnson & Johnson from $197.00 to $217.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 30th. Guggenheim boosted their target price on Johnson & Johnson from $206.00 to $227.00 and gave the stock a “buy” rating in a research note on Friday, December 5th. Finally, Citigroup upped their price target on Johnson & Johnson from $215.00 to $232.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Four equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $213.33.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.